Menu
Wechat public account

About CapitalBio

Group Profile
About CapitalBio

On February 29, 2000, at the "Tenth Science and Technology Lecture" of the General Office of the State Council held in Zhongnanhai, Dr. Jing Cheng — a Chinese scholar who had returned from overseas studies and then served as Director of the Biochip Research and Development Center at Tsinghua University - delivered a keynote presentation entitled "Biochips — A Revolutionary Technology for the Next Century" to the State Council and leaders of various ministries and commissions. In his address, he called on China to "increase investment in biochip Research and Development(R&D), promote strategic alliances among top institutions, establish a national-level engineering research center as soon as possible, rapidly develop a portfolio of proprietary technologies with Chinese intellectual property rights, and actively participate in international competition." This milestone event marked the prelude to the founding and development of CapitalBio Corporation.

On September 30, 2000, with the strong support of the State Council, the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Education, the Ministry of Health, and the Beijing municipal government, CapitalBio Corporation (hereinafter referred to as "CapitalBio") was established. It was initially founded on the strength of Tsinghua University, in partnership with Huazhong University of Science and Technology, the Chinese Academy of Medical Sciences, and the Academy of Military Medical Sciences. Since July 2022, CapitalBio has been a subsidiary of Sichuan Energy Development Group Co., Ltd. As a state-owned innovative high-tech enterprise in China's medical and healthcare industry, CapitalBio is also the first national-level biochip engineering research center in China operating as an enterprise — officially designated as the National Engineering Research Center for Beijing Biochip Technology. Headquartered in Zhongguancun Life Science Park, Changping District, Beijing, the Group has over 1,300 employees and more than 100,000 square meters of floor space dedicated to R&D, production, operations, and service. It has established R&D centers and large-scale industrialization bases in Beijing, Chengdu, and Dongguan.

Leveraging biochip technology as its core platform, CapitalBio has built a comprehensive end-to-end industrial chain for clinical diagnostics, spanning product development, manufacturing, sales, and a nationwide network of third-party independent medical laboratories. In line with the national health policy of "prevention first, with equal emphasis on traditional Chinese and Western medicines," the Company integrates modern life sciences, biomedical engineering, and artificial intelligence with traditional Chinese medicine (TCM). By systematically modernizing and scientifically advancing TCM, CapitalBio has developed a robust "Greater Health" sector that encompasses health products, health management, and rehabilitation and elderly care services. It has established a TCM modernization platform centered on AI-powered intelligent diagnostic and therapeutic devices, Molecular Herbal Medicine, and emotional wellbeing regulation, continuously driving TCM toward "upholding integrity and pursuing innovation" while expanding its global presence.

Since its inception, CapitalBio has been driven by its mission: "Committed to technological innovation for realizing the vision of better health." Continuously breaking through technological barriers both at home and abroad, the Company has expanded its footprint from clinical medicine to preventive medicine and rehabilitation medicine. Its R&D efforts are spearheaded by five core research institutes: the Institute of Health Sciences, the Institute of Health Technology, the Institute of Big Data and Artificial Intelligence, the Institute of Mobile and Wearable Technology, and the Institute of Rehabilitation Engineering. To date, CapitalBio and its industrial platforms have successfully developed dozens of proprietary products and services for clinical diagnostics and health management, both domestically and internationally. The Group has been granted over 890 patents worldwide, with a patent commercialization rate exceeding 50%. As the Chair and Secretariat of the National Technical Committee for Biochip Standardization, CapitalBio has led the formulation of 19 national standards, 9 industry standards, and 2 group standards, all of which have been promulgated and implemented. In 2007, the Company received the Second Prize of the National Award for Technological Innovation for its project on "Systematic Biochip and Related Instrumentation Development and Application"; in 2018, it received the Second Prize of the National Award for Technological Innovation again for its project on "Development and Application of a Genetic Deafness Gene Diagnostic Chip System"; in 2013, it was awarded the First Prize of the National Award for Scientific and Technological Progress for "Research and Application of Key Technologies for TCM Safety"; in 2023, it received the Second Prize of the National Award for Scientific and Technological Progress for "Establishment and Application of TCM Constitution Identification System"; and in 2025, it was awarded the Second Prize of the National Award for Scientific and Technological Progress for "Research, Development, and Application of Etiological Mechanisms and Prevention Technologies for Adverse Pregnancy and Birth Defects." These honors underscore CapitalBio's strength in scientific and technological innovation in both Western and traditional Chinese medicine.

While maintaining a strong commitment to research and innovation, CapitalBio has also been actively translating its scientific achievements into commercial applications. In the field of Western pharmaceutical R&D, CapitalBio, as the founding and largest shareholder, initiated the establishment of Chipscreen Biosciences Co., Ltd., which in 2019 became the first pharmaceutical company to list on the STAR Market of the Shanghai Stock Exchange, setting a record with an issuance P/E ratio of 467.51 times. In the field of Western medical diagnostics, the Company established its secondary holding unicorn enterprise, CapitalBio Technology Co., Ltd., which has consistently maintained a leading position in biochip and genetic testing in China. In the TCM pharmaceutical sector, through technology transfer, CapitalBio established CapitalBio Pharma Co., Ltd., a core investee company focused on TCM drug innovation. Leveraging its proprietary Molecular Herbal Database and AI-powered TCM Formulation System, the company is pioneering a new scientific pathway for the modernization and globalization of TCM. In the field of TCM diagnostics, CapitalBio established CapitalBio AiDevice Co., Ltd., a subsidiary specializing in intelligent TCM diagnostics, which integrates modern engineering technologies with AI, bioinformatics, and big data analytics to achieve digital, standardized, and intelligent TCM diagnostic solutions. In the Greater Health sector, the Company is establishing CapitalBio Health (in planning), an integrated platform combining health products, health technologies, health management, and rehabilitation and elderly care services. This platform offers a closed-loop solution of "assessment — intervention/diagnosis — treatment," enabling precise testing, scientific evaluation, and personalized health management.

Thanks to its outstanding R&D, production, marketing, and service teams, its internationally leading biochip technology platform, and its high-standard quality assurance system, CapitalBio has established strategic partnerships with nearly 100 top-tier hospitals, medical universities, and public security and judicial institutions in China. The Company has also forged alliances with global leaders in life sciences and medical diagnostics, including Roche Applied Science, Roche Diagnostics, and Thermo Fisher Scientific. By breaking the long-standing foreign monopoly on biochips, production equipment, and analytical instruments, CapitalBio has successfully exported its "Created in China" biotechnological products to more than 30 countries and regions, including Europe, the United States, and Japan. Today, CapitalBio stands as a shining symbol of China's strength and innovation in the international biotechnology and Greater Health arenas.

Copyright © 2000-2023博奥生物集团有限公司 京ICP备14023013号-3

《互联网药品信息服务资格证书》: (京) - 非经营性-2016-0047 京公网安备11011402013114号